0.00Open0.50Pre Close0 Volume2 Open Interest11.00Strike Price0.00Turnover481.09%IV45.62%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.50Extrinsic Value100Contract SizeAmericanOptions Type-0.0877Delta0.0162Gamma38.62Leverage Ratio-0.1871Theta-0.0002Rho-3.39Eff Leverage0.0033Vega
Rigel Pharmaceuticals Stock Discussion
whoa! some Dip
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
Rigel Pharmaceuticals (Nasdaq: RIGL) announced that the FDA has granted Fast Track designation to R289 for treating patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). R289, a dual inhibitor of IRAK1 and IRAK4, is currently being evaluated in a Phase 1b study. The Fast Track designation may provide benefits including more freque...
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk Mds
Let's break 30.+
27.+
Let's Get 30.+
No comment yet